Literature DB >> 10229123

High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.

D Frenkel1, M Balass, E Katchalski-Katzir, B Solomon.   

Abstract

Monoclonal antibodies raised against the N-terminal of Alzheimer's beta-amyloid peptide (betaAP) were found to modulate its fibrillar aggregation. While mAbs 6C6 and 10D5 inhibit the formation of beta-amyloid fibrils, trigger disaggregation and reversal to its non-toxic form, mAb 2H3 is devoid of these properties. MAb 2H3 binds the sequence DAEFRHD, corresponding to position 1-7 of the betaAP with high affinity (2 x 10(-9) M) similar to its binding with the whole betaAP. The EFRH peptide strongly inhibits binding of mAbs 6C6 and 10D5 to betaAP, whereas it inhibits weakly the interaction of 2H3 with betaAP. Low affinity binding of mAb 2H3 to EFRH might explain its failure in prevention of beta-amyloid formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229123     DOI: 10.1016/s0165-5728(99)00003-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

Authors:  D Frenkel; O Katz; B Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide.

Authors:  Remy Robert; Marie-Paule Lefranc; Anahit Ghochikyan; Michael G Agadjanyan; David H Cribbs; William E Van Nostrand; Kim L Wark; Olan Dolezal
Journal:  Mol Immunol       Date:  2010 Nov-Dec       Impact factor: 4.407

Review 3.  Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Authors:  David H Cribbs
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  Rational design of potent domain antibody inhibitors of amyloid fibril assembly.

Authors:  Ali Reza A Ladiwala; Moumita Bhattacharya; Joseph M Perchiacca; Ping Cao; Daniel P Raleigh; Andisheh Abedini; Ann Marie Schmidt; Jobin Varkey; Ralf Langen; Peter M Tessier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-15       Impact factor: 11.205

Review 5.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

6.  Arginine and disordered amyloid-β peptide structures: molecular level insights into the toxicity in Alzheimer's disease.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-10-08       Impact factor: 4.418

7.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

Review 8.  Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

Review 9.  Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

Authors:  Anahit Ghochikyan
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

Review 10.  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.